ArticleCurrent drug delivery2025
Nanophase: An Effective Dispersion System for the Decoction of Kushen Huaihua for the Treatment of Ulcerative Colitis.
Article in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-Assembled Safflower Polysaccharide Nanoparticles as a Targeted Drug Delivery System for Enhanced Therapy of Hepatocellular Carcinoma.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
INTRODUCTION/
objectiveIn traditional Chinese medicine, the decoction turns into a complex multiphase system following exposure to high temperatures and a complex chemical environment. However, the effective dispersion system of the decoction of Kushen Huaihua (DKH) for the treatment of ulcerative colitis (UC) has yet to be elucidated.
methodsDKH was separated into precipitated phase (DKH-P), nanophase (DKH-N), and solution phase (DKH-S) according to the particle size by ultracentrifugation dialysis, and the physicochemical properties of each phase group, such as particle size, morphology, chemical composition, and content, were analysed by TEM and HPLC. The anti-UC effects of the different phases were evaluated by ELISA and HE staining. Furthermore, the composition of the effective dispersion system and release characteristics were investigated by UV and HPLC.
resultsThe fingerprint analysis of DKH recognized 11 key components, namely Ru, Qu, Ka, Fo, Iso, Kur, SFG, OMT, OSC, MT, and SC. The content of these components in DKH-N was found to be 69.51%, 88.30%, 84.60%, 82.92%, 73.35%, 77.03%, 74.02%, 89.74%, 85.99%, 79.53%, and 85.24% of the corresponding levels in DKH, respectively. Pharmacodynamic results demonstrated that DKH-N exerted the same anti-UC effect as DKH, decreased DAI and CMDI scores, increased IL-4 and IL-10 activities, and reduced expression of IL-6, TNF-α, and MPO, which were significantly different from those of the model group (**P<0.01). Additionally, DKH-N was found to comprise 30.30% polysaccharides and 24.93% protein components. Furthermore, 11 components in DKH-N demonstrated more than 80% release in enzyme-containing simulated colonic fluid in 24 h.
conclusionDKH-N may be an effective dispersion system for DKH treatment of UC.
Indexed as
Identifiers
40012383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.